Safety and Efficacy Trial of a Targeted PSMA Fluorescent Contrast Agent (DGPR1008) for Intraoperative Imaging of Prostate Cancer

NCT07024030 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer Patients Undergoing Radical Prostatectomy

Interventions

DRUG: 0.02mg/kg
DRUG: 0.04mg/kg

Sponsor

Haitao Niu, MD